Cargando…

非小细胞肺癌中microRNAs与EGFR-TKIs继发性耐药机制的研究进展

In recent years, in non-small cell lung cancer (NSCLC) targeted therapy, especially in patients with epidermal growth factor receptor (EGFR) mutations, EGFR-tyrosine kinase inhibitors (TKI) more and more come into the clinical treatment, but EGFR-TKI resistance not only influence the drug sensitivit...

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 中国肺癌杂志编辑部 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6000411/
https://www.ncbi.nlm.nih.gov/pubmed/25539612
http://dx.doi.org/10.3779/j.issn.1009-3419.2014.12.07